68 results about "Viral Genes" patented technology

The invention provides a virus propagation dynamic prediction method based on a multi-strain multi-region population model and related equipment. The method comprises the following steps: acquiring historical epidemic situation related data of a target area, wherein the historical epidemic situation related data comprises epidemic situation data, virus gene sequence data, population flow data and epidemic situation management policy data related to a target virus in a past time period of each area; arranging the population flow data into an asymmetric population flow matrix between different regions every day; sorting epidemic prevention grades corresponding to different epidemic situation management policies according to the epidemic situation management policy data; and constructing a multi-strain and multi-region population model based on epidemic situation data, virus gene sequence data, a population flow matrix and epidemic prevention grades corresponding to different epidemic situation management policies by taking StatPOMP as a model construction framework, and generating virus propagation dynamic prediction information based on the model. The prediction accuracy of the virus propagation trend can be improved.

The invention discloses a live pig epidemic prevention and control flow regulation system and method based on big data, and relates to the technical field of animal health information, and the method comprises the steps: recognizing abnormal live pig signals and track intersection features of structured epidemic prevention feature data through an intelligent algorithm, comparing the virus gene difference degree, constructing a virus propagation network diagram, and carrying out the analysis of the virus propagation network diagram; outputting a high-risk propagation node map; constructing an aerosol dynamics three-dimensional space model by taking a super propagation hub node of the high-risk propagation node map as an original point and combining culture environment parameters, simulating a virus air diffusion path, and generating an environment propagation thermal distribution map; fusing the high-risk propagation node map and the environment propagation thermal distribution map, identifying a cross infection area through a multi-dimensional risk superposition model to perform risk dynamic grading, and outputting a grading early warning report; according to the invention, breakthrough improvement of the live pig epidemic prevention and control capability is realized, key nodes and potential risk areas of epidemic propagation can be accurately identified, and the pertinence of prevention and control measures is improved.

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleotides, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The invention discloses a virus gene sequence host prediction method and system, and belongs to the technical field of biological information analysis, and the method comprises the steps: dividing a virus gene sequence into ordered k-mer word sequences, and carrying out the vectorization of the k-mer word sequences through a pre-trained BERT language model, and obtaining an embedded vector; mapping the embedded vector of the high-dimensional space into a low-dimensional space with a fixed dimension by adopting an average pooling method, and reducing the embedded dimension to obtain a feature vector representing an original gene sequence; the feature vectors are input into a pre-trained classification network model to predict the likelihood that the sequence is infected with a particular host. According to the method, the complete virus gene sequence is directly used as input, so that information loss possibly caused by dependence on statistical characteristics is avoided, and the accuracy of characteristic extraction is remarkably improved.

The invention provides a rapid processing method for HPV (human papillomavirus) gene sequence data. The method relates to the technical field of data processing, and comprises the following steps: acquiring and integrating HPV sequence data, host transcriptome data and clinical association data to form a comprehensive input matrix; performing feature screening on the comprehensive input matrix by adopting a bee colony optimization algorithm based on reinforcement learning to obtain an optimal feature subset; according to the bee colony optimization algorithm, global search of the bee colony algorithm is combined with a dynamic decision-making mechanism of reinforcement learning, and a feature selection strategy is dynamically adjusted; and constructing an HPV subtype accurate typing and variation detection model based on multi-task deep learning, performing deep coding and weighted fusion on the optimal feature subset through an unstable attention mechanism, and outputting two key prediction results of subtype probability and mutation site probability. According to the method, the accuracy and biological interpretability of virus typing and variation detection are improved, and efficient extraction and multi-task accurate recognition of high-dimensional features are realized.

Herein is reported a method for producing a recombinant adeno-associated viral particle preparation (rAAVp), the method comprising the steps of culturing a mammalian cell comprising an expression cassette directed against: a non-adeno-associated viral gene interposed between two AAV inverted terminal repeats (ITRs), and thereby producing the rAAVp; an adeno-associated virus rep gene; an adeno-associated virus cap gene; an adeno-associated virus E1A gene; an adeno-associated virus E1B gene; an adeno-associated virus E2A gene; an adeno-associated virus E4orf6; and an adeno-associated virus VA RNA gene, wherein the culturing is carried out at a pH value in the range of pH 7.4 to pH 7.6 and including a terminal value. The yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.4 to pH 7.6 and including a terminal value is higher than the yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.0 to pH 7.2 and including a terminal value, and the yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.4 to pH 7.6 and including a terminal value is lower than the yield of the rAAVp produced by the culture performed at a pH value in the range of pH 7.0 to pH 7.2. And the rAAVp produced by the culture at a pH value in the range of pH 7.4 to pH 7.6 and including an endvalue has a higher percentage of intact particles than the rAAVp produced by the culture at a pH value in the range of pH 7.0 to pH 7.2 and including an endvalue.

The invention provides a vector and a method for expressing astaxanthin by using nicotiana benthamiana leaves, which are characterized in that plant virus expression vectors of calendula astaxanthin synthesis related genes AdKC and AdKeto and plant virus gene silencing (RNAi) vectors of nicotiana benthamiana carotenoid cleavage dioxygenase 1 (CCD1) are respectively constructed; the agrobacterium tumefaciens of the three vectors are mixed and infiltrated into the boeng tobacco leaves to obtain the leaves for expressing the astaxanthin. According to the invention, the expression of the nicotiana benthamiana CCD1 gene is interfered while the AdKC and AdKeto genes are expressed in the nicotiana benthamiana leaves, so that the content of astaxanthin expressed in the nicotiana benthamiana leaves is increased.

Disclosed is a method of differentiating empty capsids from full capsids or loaded and unloaded non-viral gene therapy vectors in a viral preparation. The method comprises the steps of: a) providing a preparation of viral particles or gene therapy vectors; b) subjecting the preparation to interferometric scattering mass cytometry (ISCAMS) in an interferometric scattering microscope to generate mass distribution data of the viral particles; c) determining from the mass distribution data the level of empty capsids and capsids containing genomes or the level of loaded and unloaded vectors in the viral particles.

Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.

Provided are gene therapy vectors designated MEV-GTVs, which are MEVs that contain an ITR-containing plasmid (also referred to as a minigene plasmid) that comprises Inverted Terminal Repeats (ITRs), such as viral ITRs, and nucleic acid encoding a product of interest, and optionally regulatory sequences. The ITRs serve to circularize the minigene plasmid. The plasmids do not contain additional viral components, so that resulting DNA is not encapsulated in a viral capsid or envelop and is not replicated by viral genes. The plasmids can be inserted into bacterial plasmids for propagation.

This document relates to materials and methods for treating cancer. For example, this document provides materials and methods for using PD-L1 targeting domains in bispecific chimeric polypeptides, chimeric transmembrane polypeptides, genetically modified viruses, nucleic acid vectors, and / or fusion-inducing cells to treat cancer.

The present disclosure relates to a genetically modified virus comprising at least one nucleic acid molecule encoding a cytokine that recruits and / or activates T cells and a class II major histocompatibility complex transactivator (CIITA), as well as pharmaceutical compositions comprising said genetically modified virus and methods of treating cancer with said genetically modified virus.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and / or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and / or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.

Herein is reported a method for producing recombinant adeno-associated viral particle preparation (rAAVp) comprising the step of cultivating a mammalian cell comprising expression cassettes for a non-adeno-associated viral gene, which is interspaced between two AAV inverted terminal repeats (ITRs), an adeno-associated virus rep gene, an adeno-associated virus cap gene, an adeno-associated virus E1A gene, an adeno-associated virus E1B gene, an adeno-associated virus E2A gene, an adeno-associated virus E4orf6 and an adeno-associated virus VA RNA gene, and thereby producing the rAAVp, wherein the cultivating is at a pH value in the range of and including pH 7.4 to pH 7.6. The yield of the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 is higher than the yield of a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2 and the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 has a higher percentage of full particles than a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2.

The present disclosure provides a method of inhibiting telomerase activity to reduce human herpesvirus (e.g., HMCV, EBV, HSV-1, and / or HHV-6 / 7 / 8) replication. The method comprises treating cells with a telomerase inhibitor prior to and after HCMV infection. The telomerase inhibitor may be a pharmaceutical inhibitor such as BIBR1532 or MST312, or an siRNA construct targeting the hTERT catalytic subunit of telomerase. Treatment with the telomerase inhibitor results in reduced viral titer, decreased viral gene expression, and diminished viral protein levels across different temporal phases of herpesvirus infection. The method provides a novel approach for inhibiting herpesvirus replication through targeting of host cell telomerase activity.

The present invention relates to oncolytic vaccinia viruses and recombinant viruses and methods of use thereof. In particular, the present invention provides a cloned vaccinia virus strain exhibiting enhanced anti-tumor properties and / or reduced immunogenicity, as well as a recombinant vaccinia virus derived therefrom. The present invention also provides recombinant oncolytic virus strains comprising an inactivated mutation in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses (e.g., vaccinia viruses, including recombinant vaccinia viruses) provided herein are useful as oncolytic viral therapies (e.g., oncolytic vaccinia viral therapies) for the treatment of cancer. The invention also provides pharmaceutical compositions of the virus, such as vaccinia virus, and methods and uses of the virus, such as vaccinia virus, for the treatment of cancer, as well as nucleic acids encoding the virus.

This disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a gene cassette encoding a target sequence. In some embodiments, the target sequence encodes a microRNA and / or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and / or the second ITR is an ITR of a non-adeno-associated virus (AAV). This disclosure also provides methods of treating a metabolic liver disorder in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide so encoded.

This invention relates to oncolytic vaccinia viruses, recombinant viruses thereof, and methods of use. Specifically, the invention provides vaccinia virus clone lines and recombinant vaccinia viruses derived therefrom, said vaccinia virus clone lines exhibiting enhanced antitumor properties and / or reduced immunogenicity. The invention also provides recombinant oncolytic virus lines comprising inactivating mutations in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses provided by this invention (such as vaccinia viruses, including recombinant vaccinia viruses) can be used as oncolytic virus therapies (such as oncolytic vaccinia virus therapy) for the treatment of cancer. The invention also provides pharmaceutical compositions of viruses (such as vaccinia viruses), methods and uses of viruses (such as vaccinia viruses) for the treatment of cancer, and nucleic acids encoding said viruses.

The invention discloses a cationic polymer gene delivery vector as well as a preparation method and application thereof, and the cationic polymer gene delivery vector is a polymer prepared from monomers with different hydrophilic and hydrophobic properties and polyglycidyl amine in two modes of block copolymerization and random copolymerization. The monomer polymerized with the polymer is at least one of propylene oxide, epoxybutane, epoxypentane, epoxyhexane, epoxyheptane and styrene oxide; wherein the number of the hydrophobic unit units in all repetitive units of the polymer accounts for 10%-50%. The cationic polymer gene delivery vector provided by the invention, as a non-viral gene transfection vector, has relatively low cytotoxicity and relatively good gene transfection capability.

The present invention relates to a chimeric poxvirus with improved anticancer activity (higher cancer cell killing capacities and better tumor selectivity), as well as variant version thereof with one or more altered viral genes, recombinant versions thereof comprise one or more nucleic acid(s) of interest and recombinant variant versions thereof, all of which may be included in a composition and used for the treatment of a disease, in particular proliferative disease, notably cancers.

The invention discloses an application of etoposide in preparation of anti-rabies virus drugs, and proves that the clinical anti-tumor drug etoposide has remarkable anti-rabies virus activity on cell and animal levels for the first time, and plays an antiviral role in vitro and vivo by inhibiting virus replication and reducing virus gene and protein expression. The invention provides a brand-new medical application for etoposide, namely provides a new medicine and a technical scheme for preparing a rabies virus, and has important significance for solving the problem of clinical treatment of rabies.

The present invention provides an apparatus, method, and system for measuring the attributes of a viral gene delivery vehicle sample through isolation. [Solution] In one embodiment, the method, system, and computer program product perform a series of logical operations to analyze a viral gene delivery vehicle sample in a set of analytical instruments including at least one separation instrument, at least one static light scattering instrument, and at least two concentration detectors, thereby determining the capsid protein mass of the sample m A And the sample modification factor mass m B And the molar mass M of the modifying factor in the sample B This results in the molar mass of the capsid protein in the sample M A The data source receives the molar mass of the capsid protein, the injection volume v of the sample from the injection volume data source, and the total VGDV particle concentration C of the sample. A This includes performing a series of logical operations to calculate [something].

The present disclosure provides, for instance, polymer-lipid hybrid nanoparticle compositions and methods of making and using them. The polymer-lipid hybrid nanoparticle may comprise, for example, poly(lactic-co-glycolic) acid (PLGA), polyethylenimine (PEI), and D-Lin-MC3-DMA (MC3). The polymer-lipid hybrid nanoparticle can be used to deliver, for example, nucleic acids and small molecules, cells.

According to the present invention, cultured cells are pretreated with a candidate strain and then infected with a virus, and a strain having an antiviral effect is selected by using, as an indicator, the expression of a viral gene or protein in the recovered cells. By the screening method, a Lactobacillus delbrueckii subsp. delbrueckii THU5 strain (accession number: NITE BP-04062) and a Limosilactobacillus reuteri THU6 strain (accession number: NITE BP-04063), which have a rotavirus infection inhibitory effect, were obtained. These strains, as immunobiotics, have an effect against viral infections, in particular, a rotavirus infectious disease.

The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.

Provided herein are polynucleotides comprising a nucleotide sequence encoding a biomolecule, such as human alpha-galactosidase A, a nucleotide sequence encoding a promoter, such as a hepatocyte-specific promoter or a hepatocyte-muscle cell bispecific promoter, or a nucleotide sequence encoding an expression cassette, such as a human alpha-galactosidase A expression cassette. Also provided herein are promoters, expression cassettes, vectors, host cells, gene delivery systems (e.g., recombinant viral particles, such as recombinant adeno-associated virus (AAV) particles and non-viral gene delivery systems), related pharmaceutical compositions, and methods of using the same. Such compositions and methods are particularly suitable for gene therapy, particularly for lysosomal storage disorders, including Fabry disease.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

To provide a VLP vaccine derived from the genus Enterovirus which is safe and has good stability.SOLUTION: The VLP vaccine of the present invention is highly safe because it uses VLPs having no viral internal gene as an antigen, and has good stability because it is fixed with formaldehyde in a high salt concentration.SELECTED DRAWING: None